Literature DB >> 8891148

Contributions of individual mechanisms to fluoroquinolone resistance in 36 Escherichia coli strains isolated from humans and animals.

M J Everett1, Y F Jin, V Ricci, L J Piddock.   

Abstract

Twenty-eight human isolates of Escherichia coli from Argentina and Spain and eight veterinary isolates received from the Ministry of Agriculture Fisheries and Foods in the United Kingdom required 2 to > 128 micrograms of ciprofloxacin per ml for inhibition. Fragments of gyrA and parC encompassing the quinolone resistance-determining region were amplified by PCR, and the DNA sequences of the fragments were determined. All isolates contained a mutation in gyrA of a serine at position 83 (Ser83) to an Leu, and 26 isolates also contained a mutation of Asp87 to one of four amino acids: Asn (n = 14), Tyr (n = 6), Gly (n = 5), or His (n = 1). Twenty-four isolates contained a single mutation in parC, either a Ser80 to Ile (n = 17) or Arg (n = 2) or a Glu84 to Lys (n = 3). The role of a mutation in gyrB was investigated by introducing wild-type gyrB (pBP548) into all isolates; for three transformants MICs of ciprofloxacin were reduced; however, sequencing of PCR-derived fragments containing the gyrB quinolone resistance-determining region revealed no changes. The analogous region of parE was analyzed in 34 of 36 isolates by single-strand conformational polymorphism analysis and sequencing; however, no amino acid substitutions were discovered. The outer membrane protein and lipopolysaccharide profiles of all isolates were compared with those of reference strains, and the concentration of ciprofloxacin accumulated (with or without 100 microM carbony cyanide m-chlorophenylhydrazone [CCCP] was determined. Twenty-two isolates accumulated significantly lower concentrations of ciprofloxacin than the wild-type E. coli isolate; nine isolates accumulated less then half the concentration. The addition of CCCP increased the concentration of ciprofloxacin accumulated, and in all but one isolate the percent increase was greater than that in the control strains. The data indicate that high-level fluoroquinolone resistance in E. coli involves the acquisition of mutations at multiple loci.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8891148      PMCID: PMC163538     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  34 in total

1.  Structure and activities of Escherichia coli DNA gyrase.

Authors:  C L Peebles; N P Higgins; K N Kreuzer; A Morrison; P O Brown; A Sugino; N R Cozzarelli
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1979

2.  DNA sequence of the E. coli gyrB gene: application of a new sequencing strategy.

Authors:  T Adachi; M Mizuuchi; E A Robinson; E Appella; M H O'Dea; M Gellert; K Mizuuchi
Journal:  Nucleic Acids Res       Date:  1987-01-26       Impact factor: 16.971

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  A sensitive silver stain for detecting lipopolysaccharides in polyacrylamide gels.

Authors:  C M Tsai; C E Frasch
Journal:  Anal Biochem       Date:  1982-01-01       Impact factor: 3.365

5.  PhoE protein pore of the outer membrane of Escherichia coli K12 is a particularly efficient channel for organic and inorganic phosphate.

Authors:  J Korteland; J Tommassen; B Lugtenberg
Journal:  Biochim Biophys Acta       Date:  1982-09-09

6.  Mutations producing resistance to norfloxacin in Pseudomonas aeruginosa.

Authors:  K Hirai; S Suzue; T Irikura; S Iyobe; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

7.  Nalidixic acid-resistant mutations of the gyrB gene of Escherichia coli.

Authors:  J Yamagishi; H Yoshida; M Yamayoshi; S Nakamura
Journal:  Mol Gen Genet       Date:  1986-09

8.  Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity.

Authors:  M Gellert; K Mizuuchi; M H O'Dea; T Itoh; J I Tomizawa
Journal:  Proc Natl Acad Sci U S A       Date:  1977-11       Impact factor: 11.205

9.  Repressor mutations in the marRAB operon that activate oxidative stress genes and multiple antibiotic resistance in Escherichia coli.

Authors:  R R Ariza; S P Cohen; N Bachhawat; S B Levy; B Demple
Journal:  J Bacteriol       Date:  1994-01       Impact factor: 3.490

10.  Efflux-mediated fluoroquinolone resistance in Staphylococcus aureus.

Authors:  G W Kaatz; S M Seo; C A Ruble
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

View more
  117 in total

1.  High-level fluoroquinolone-resistant clinical isolates of Escherichia coli overproduce multidrug efflux protein AcrA.

Authors:  A Mazzariol; Y Tokue; T M Kanegawa; G Cornaglia; H Nikaido
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

Review 2.  Efflux-mediated resistance to fluoroquinolones in gram-negative bacteria.

Authors:  K Poole
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

3.  Alterations in GyrA and ParC associated with fluoroquinolone resistance in Enterococcus faecium.

Authors:  N A el Amin; S Jalal; B Wretlind
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

4.  Impact of gyrA and parC mutations on quinolone resistance, doubling time, and supercoiling degree of Escherichia coli.

Authors:  S Bagel; V Hüllen; B Wiedemann; P Heisig
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

5.  Alteration of Escherichia coli topoisomerase IV to novobiocin resistance.

Authors:  Christine D Hardy; Nicholas R Cozzarelli
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

6.  Development of a rapid assay for detecting gyrA mutations in Escherichia coli and determination of incidence of gyrA mutations in clinical strains isolated from patients with complicated urinary tract infections.

Authors:  S Ozeki; T Deguchi; M Yasuda; M Nakano; T Kawamura; Y Nishino; Y Kawada
Journal:  J Clin Microbiol       Date:  1997-09       Impact factor: 5.948

7.  Risk factors for fecal quinolone-resistant Escherichia coli in Mexican children.

Authors:  Mussaret B Zaidi; Emma Zamora; Pilar Diaz; Linda Tollefson; Paula J Fedorka-Cray; Marcia L Headrick
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

8.  Retrospective analysis of the first clonal outbreak of nalidixic acid-resistant Shigella sonnei shigellosis in Israel.

Authors:  D Dagan; N Orr; M Yavzori; Y Yuhas; D Meron; S Ashkenazi; D Cohen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2002-12-10       Impact factor: 3.267

9.  Role of topoisomerase mutations and efflux in fluoroquinolone resistance of Bacteroides fragilis clinical isolates and laboratory mutants.

Authors:  Vito Ricci; Marnie L Peterson; John C Rotschafer; Hannah Wexler; Laura J V Piddock
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

10.  Characterization and studies of the cellular interaction of native colonization factor CS6 purified from a clinical isolate of enterotoxigenic Escherichia coli.

Authors:  Abhisek Ghosal; Rudra Bhowmick; Rajat Banerjee; Sandipan Ganguly; S Yamasaki; T Ramamurthy; T Hamabata; Nabendu Sekhar Chatterjee
Journal:  Infect Immun       Date:  2009-02-23       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.